1 / 2

Pomahope 3mg capsule - Pomalidomide | Myapplepharma

Pomahope 3mg is a Glenmark Pharmaceuticals product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide, It is available as orally bioavailable thalidomide derivative with various therapeutic activities such as;Immuno modulatory, Anti-angiogenesis, Anti-neoplastic

RobbieRoyce
Download Presentation

Pomahope 3mg capsule - Pomalidomide | Myapplepharma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. POMAHOPE 3MG DESCRIPTION Pomahope 3mg is a Natco pharma product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide. Pomahope 3mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomahope 3mg is similar to thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may leads to severe liver injury. Pomahope 3mg is involved in the treatment for regression & unmanageable multiple myeloma. Pomahope 3mg is used in the patients who are failing to response for Lenalidomide treatment. Pomahope 3mg is used in combination with dexamethasone. INDICATION The major therapeutic indication of Pomahope 3mg is involved in the treatment of multiple myeloma. This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomahope 3mg Pomahope 3mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor. Pomahope WORKS Pomahope 3mg exhibits various activities like; Anti-neoplastic activity Prohibits proliferation Promote apoptosis of hematopoietic cancer cells Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis Immuno modulatory Boosted the T-cells & natural killer cell mediate immunity. The drug is prohibited the formation of pro- inflammatory cytokines by monocytes. Anti-angiogenesis Interfere with formation of new vessels and leads to inhibit the cell division.

  2. DOSAGE & ADMINISTRATION During hematological toxicities; Neutropenia : ANC (absolute neutrophils count) <500/mcl: Postpone the Pomahope therapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomahope 3mg daily. Thrombocytopenia : Platelets count <25,000/mcL: postpone the Pomahope treatment & follow the CBC >50,000/mcL: continue 3mg of Pomahope Pomahope 3mg with potent CYP1A2 inhibitor : During this combination reduce the dose of Pomahope by 50% In renal impairment : Initial dose of Pomahope is 3mg In hepatic impairment : Mild to moderate condition, an initial dose of Pomahope is 3mg; in severe condition, the initial dose of Pomahope is 2mg. DRUG INTERACTION Pomalidomide metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomahope 3mg with CYP1A2 drugs like Fluoxamine causes elevation of Cmax & AUC of Pomalidomide and concludes as increased concentration of Pomahope leads to higher extent of adverse effects associated with Pomahope In this condition, reduce the dose of Pomahope 3mg and recommended. STORAGE Pomahope 3mg should be stored at room temperature of 20° to 25° Protect from light Kept in dry & cool place

More Related